Related Experiment Video
Updated: Aug 25, 2026
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Advances in respiratory syncytial virus vaccine development
Martin C J Kneyber1, Jan L L Kimpen
1VU University Medical Center, Department of Paediatric Intensive Care, Office 8D11, PO Box 7057, 1007 MB Amsterdam, The Netherlands. m.kneyber@vumc.nl
Insights
Developing a safe and effective respiratory syncytial virus (RSV) vaccine is crucial, especially for high-risk children. Current vaccine candidates face challenges with efficacy and side effects, necessitating further research.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Respiratory syncytial virus (RSV) is a primary cause of respiratory infections, particularly severe in infants with underlying health conditions.
- Children with chronic lung or congenital heart disease face elevated risks for severe RSV disease.
- RSV vaccine development is a critical area of research due to the virus's significant public health impact.
Purpose of the Study:
- To review recent advancements in the development of vaccines targeting respiratory syncytial virus (RSV).
- To discuss the progress and challenges associated with different RSV vaccine candidates.
- To highlight the ongoing efforts in creating effective RSV immunization strategies.
Main Methods:
- Review of current literature on RSV vaccine development.
- Analysis of clinical trial data for live attenuated and subunit vaccines.
- Evaluation of immunogenicity and safety profiles of candidate vaccines.
Main Results:
- Live attenuated and subunit RSV vaccines have shown immunogenicity but are associated with upper respiratory tract infection symptoms.
- Purified F protein vaccines are effective in seropositive children but also cause respiratory symptoms.
- One promising subunit vaccine (BBG2Na) development was discontinued despite Phase III trials.
Conclusions:
- Current RSV vaccine candidates, including live attenuated and subunit types, present safety and efficacy challenges.
- The development of safe and effective RSV vaccines remains an ongoing challenge, particularly for vulnerable infant populations.
- Continued research and innovation are essential to overcome hurdles in RSV vaccine development and protect at-risk individuals.
Abstract:
Respiratory syncytial virus (RSV) is the most important causative agent of respiratory tract infections. Young children with chronic lung or congenital heart disease are at increased risk for severe disease. Intensive research into a candidate vaccine has yielded live attenuated vaccines and subunit vaccines, which have been studied in humans. Although immunogenic, occurrence of upper respiratory tract infection symptoms with live attenuated vaccine prohibits evaluation in young infants. Subunit vaccines include purified F protein (PFP-1 and -2) and BBG2Na. PFP vaccines are effective in seropositive children, but also induce upper respiratory symptoms. BBG2Na was being investigated in phase III clinical trials, however, further development has now been discontinued. This review discusses recent advances in RSV vaccine development.
